Earnings Ahead

HOTH - Hoth Therapeutics

2.94 -0.13 -4.24

Hoth Therapeutics

Hoth Therapeutics

About

Profile


Headquarters


Intraday

High
-
Low
-

52-week

High
-
Low
-

HOTH



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Hoth adds 39% as mouse model shows proof-of-concept for Alzheimer’s candidate
  • Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
  • Hoth extends Washington Uni. Alzheimer's mouse model study with its HT-ALZ therapeutic
  • Hoth adds drug/device product HT-TBI to pipeline as potential therapy for brain injury
  • Hoth Therapeutics slides on pricing $7.0M stock offering
  • Hoth Therapeutics slides on public offering of common stock
  • Hoth Therapeutics surges on preclinical data for cancer therapy
  • Hoth Therapeutics spikes on FDA’s Orphan Drug status for mastocytosis therapy
  • Hoth Therapeutics pares gains following Alzheimer's data; shares down 20%
  • Hoth highlights promise of Alzheimer’s therapy with data from animal study
  • Hoth inks research agreement for development of mRNA cancer therapy
  • Hoth Therapeutics gets clearance for BioLexa atopic dermatitis study in Australia
  • Hoth Therapeutics reports positive results from first cohort of BioLexa trial
  • Hoth Therapeutics' jumps 9% after mRNA 'Frameshifting' therapy reduces size, spread of cancer cells
  • Hoth Therapeutics initiates preclinical study of HT-ALZ for Alzheimer's disease
  • Hoth Therapeutics posts confirmatory results from in vivo HT-003 acne study
  • Hoth Therapeutics shares rise on BioLexa atopic dermatitis data
  • Hoth Therapeutics extends agreement for experimental antibiotic
  • Hoth Therapeutics pops 4% on positive preclinical results of HT-KIT in mast cell cancers
  • Hoth Therapeutics to provide an update on endocannabinoid therapeutic on May 18

Earnings History

Date EPS / Forecast Revenue / Forecast
November 16, 2021 - / -0.175 - / -
August 19, 2021 -0.24 / -0.17 - / -
May 19, 2021 -0.24 / -0.24 - / -
March 8, 2021 -0.05 / -0.1 - / -
December 2, 2020 -0.16 / -0.1 - / -
September 2, 2020 -0.2 / -0.17 - / -
June 3, 2020 -0.18 / -0.17 - / -
February 26, 2020 -0.38 / -0.16 - / -
November 27, 2019 -0.17 / -0.13 - / -
August 28, 2019 -0.13 / -0.11 - / -
August 14, 2019 -0.15 / - - / -
Date Price Open High Low Vol Change ER
Mar 15 0.5436 0.5500
0.5500
0.5201
298.71K 4.74%
Mar 14 0.5190 0.5900
0.5900
0.4900
1.82M -14.93%
Mar 11 0.6101 0.6445
0.6474
0.5910
4.05M -23.43%
Mar 10 0.7968 0.6000
0.9400
0.5740
15.64M 38.79%
Mar 9 0.5741 0.5551
0.6000
0.5430
125.65K 3.42%
 
Mar 8 0.5551 0.5600
0.5600
0.5000
342.44K -1.82%
Mar 7 0.5654 0.6000
0.6000
0.5533
205.12K -4.97%
Mar 4 0.5950 0.6067
0.6295
0.5950
121.56K -1.54%
Mar 3 0.6043 0.6000
0.6150
0.5850
89.86K 0.72%
Mar 2 0.6000 0.5900
0.6277
0.5900
148.07K 1.71%
Mar 1 0.5899 0.5872
0.6095
0.5701
135.36K 3.49%
Feb 28 0.5700 0.5818
0.6100
0.5320
178.51K -3.24%
Feb 25 0.5891 0.5700
0.6100
0.5601
126.10K 3.35%
Feb 24 0.5700 0.5644
0.5844
0.5151
128.96K 0%
Feb 23 0.5700 0.5700
0.5888
0.5501
73.59K 0.02%
Feb 22 0.5699 0.5700
0.5888
0.5500
153.81K 0.87%
Feb 18 0.5650 0.5796
0.5888
0.5320
343.30K 0.18%
Feb 17 0.5640 0.5950
0.6000
0.5620
189.72K -7.54%
Feb 16 0.6100 0.6050
0.6181
0.5886
53.95K -0.59%